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Abstract: Hepatocellular cancer (HCC) is currently the third leading cause of cancer death 
worldwide. The prognosis of patients diagnosed with late-stage disease is dismal due to high 
resistance to conventional systemic therapies. The introduction of sorafenib, despite its limited 
efficacy, as the standard systemic therapy for advanced HCC has paved a way for targeted molecu-
lar therapies for HCC. Fibroblast growth factor (FGF) signaling plays an important role in the 
developing embryo and the adult. The FGF signaling pathway is often hijacked by cancer cells, 
including HCC. Several alterations in FGF signaling correlate with poor outcome in HCC patients, 
suggesting that this family of signaling molecules plays an important role in the development of 
HCC. Multikinase inhibitors targeting FGF signaling are currently under investigation in clinical 
trials. This review discusses the current understanding of the biological and clinical implications 
of aberrant FGF signaling in the prognosis, diagnosis, and treatment of HCC.
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Introduction
The mortality rate for hepatocellular carcinoma (HCC), despite a plethora of 
treatment options, remains high. HCC is the fifth most common cancer worldwide 
and is currently the third leading cause of cancer mortality.1 Eighty percent of new 
cases occur in developing countries, but the incidence is increasing in economically 
developed regions such as Japan, Western Europe, and the USA, which may be 
attributable to the greater prevalence of hepatitis C virus (HCV) infection as well 
as an increase in obesity and diabetes levels in these areas.2–4 The 5-year survival 
rate for patients with HCC is only 7%, and very few patients survive more than 
12 months.5 Most HCC patients present with late-stage disease, only 30% are surgi-
cally resectable (although resection can improve 5-year survival rates of up to 70%, 
even in these resectable patients, there is a high risk of tumor recurrence, as high as 
50% after 5 years)6 given that more than 80% have underlying cirrhosis,7 a known 
predisposing factor for development of new HCC,8 and only 30% of patients are 
eligible for repeat resection.7 The treatment options available for patients with late-
stage disease include ablation, selective chemotherapy and/or embolization, selec-
tive radiotherapy, and systemic chemotherapy, but the prognosis is dismal (5-year 
survival rate approximately 10%).9
Patients with advanced HCC have very limited treatment options, and sorafenib is the 
only known targeted therapy approved for those with advanced, unresectable, or meta-
static HCC, after demonstrating significant improvement in overall survival of patients 
in two pivotal randomized Phase III clinical trials (the Sorafenib HCC Assessment 
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Randomized Protocol [SHARP] and Asia-Pacific trials).10,11 
Sorafenib was developed as an inhibitor of vascular endothe-
lial growth factor (VEGF) receptors 2 and 3, platelet-derived 
growth factor (PDGF) receptor, and intracellular Raf kinases; 
however, its mechanism of action remains unknown, and 
sorafenib demonstrates only modest efficacy even in patients 
with preserved liver function (10.7 months with sorafenib 
versus 7.9 months with placebo in the SHARP trial). Further, 
sorafenib is associated with significant toxicity, which may 
impact on its efficacy.10 Thus, it is imperative that new alter-
native therapeutics are investigated in order to optimize the 
outcomes for patients with advanced HCC (this may include 
synergistic combinations to block several pathways or agents, 
which will offer hope to patients who are refractory to treat-
ment with sorafenib).12 As such, other small molecules such 
as brivanib (a VEGF receptor 2 inhibitor) and erlotinib (an 
epidermal growth factor inhibitor), and monoclonal antibodies 
such as bevacizumab (a VEGF A inhibitor) and cetuximab 
(an epidermal growth factor inhibitor), are currently being 
studied in patients with HCC.13
Increasing knowledge of the oncogenic processes and 
signaling pathways that regulate tumor development in HCC, 
as well as the advent of genome wide studies, have identi-
fied potential therapeutic targets. Further, several molecular 
subtypes of HCC have been identified.14 Recent data highlight 
the interplay between surrounding tissue (stroma) and the 
tumor, suggesting that HCC is a complex process leading to 
alterations in several signaling pathways.15,16 Among these 
pathways, it appears the fibroblast growth factor (FGF) sig-
naling axis may play an important role in the development 
of HCC.17–21
FGF signaling
The first FGF was discovered as a mitogen for cultured fibro-
blasts over three decades ago.22 FGFs are crucial modulators 
of cellular proliferation, differentiation, embryonic develop-
ment, and organogenesis.23 The mammalian FGF family 
comprises 18 secreted FGF ligands that signal through four 
high affinity transmembrane FGF receptors. A fifth recep-
tor, FGF receptor 5, has no tyrosine kinase activity and is 
thought to negatively regulate signaling by dimerizing with 
FGF receptors 1–4 and blocking transphosphorylation.24 
FGFs also bind to heparan sulfate proteoglycans, low affinity 
receptors that do not transmit a biological signal but function 
as accessory molecules.25,26 Unlike the canonical FGFs that 
act as autocrine and paracrine factors, FGF15/19, FGF21, and 
FGF23 have a low affinity for heparan sulfate proteoglycans, 
function as endocrine hormones, and exert actions distant to 
the tissues from which they are secreted. These molecules 
require single pass transmembrane glycoproteins, known as 
klotho or βklotho proteins, to act as coreceptors to bind and 
activate FGF receptors.27
FGF receptors are comprised of an extracellular ligand-
binding domain linked to an intracellular catalytic protein 
kinase core via a single pass transmembrane domain. Normally, 
the extracellular ligand binding domain of the receptor con-
sists of three immunoglobulin domains (designated D1–3), 
a stretch of 7–8 acidic residues in the region connecting D1 
to D2 (designated the “acid box”), and a conserved positively 
charged region in D2 that binds heparin.28 A feature unique 
to the FGF receptor family of receptor tyrosine kinases is 
the variety of isoforms that are generated by alternative 
splicing of FGF receptor mRNAs.29 Many splice isoforms 
have been described, the principal ones being alternative 
splicing of the D3 domain of FGF receptors 1–3, which 
determines the sequence of the carboxy-terminal half of 
the third membrane-proximal immunoglobulin domain and 
strongly dictates ligand-receptor binding (Table 1). In general, 
FGF receptor b isoforms are expressed on epithelial 
Table 1 Specificity of ligands for FGF receptor isoforms
FGF subfamily FGF FGFR specificity
FGF1 FGF1 All FGFRs
FGF2 FGFR1c, FGFR3c . FGFR2c, 
FGFR1b, FGFR4
FGF4 FGF4
FGF5 FGFR1c, FGFR2c . FGFR3c, FGFR4
FGF6
FGF7 FGF3
FGF7 FGFR2b . FGFR1b
FGF10
FGF22
FGF8 FGF8
FGF17
FGF18
FGFR3c . FGFR4 . FGFR2c . 
FGFR1c .. FGFR3b
FGF9 FGF9
FGF16
FGF20
FGFR3c . FGFR2c . FGFR1c, 
FGFR3b .. FGFR4
FGF19 FGF19
FGF21 FGFR1c, FGFR2c, FGFR3c, FGFR4
FGF23 (weak activity)
FGF11 FGF11
FGF12
FGF13 No known activity
FGF14
Notes: FGF receptors 1–3 are alternatively spliced, while FGF receptor 4 is not. 
This alternative splicing event is regulated in a tissue-specific manner and dramatically 
affects ligand binding. For example, epithelially expressed FGF receptor 2b can be 
activated by mesenchymal FGF7 and FGF10; however, these ligands show no activity 
towards mesenchymally expressed FGF receptor 2c. 
Abbreviations: FGF, fibroblast growth factor; FGFR, fibroblast growth factor 
receptor.
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cells, while FGF receptor c isoforms are restricted to 
mesenchymal cell types, this being particularly true for FGF 
receptors 2 and 3.30 This lineage-specific expression of the 
FGF receptor b and c isoforms allows establishment of para-
crine signaling loops between epithelial and mesenchymal 
tissues during development.
Ligand-induced dimerization of FGF receptors leads to 
a conformational shift in receptor structure and release of 
kinase autoinhibition. This results in a 50–100-fold increase 
in kinase activity of the receptor, resulting in activation 
through transphosphorylation of several tyrosine residues 
within the intracellular domain.31,32 This phosphorylation 
increases the receptor kinase activity, generating dock-
ing sites for downstream signaling molecules and conse-
quent activation of multiple signal transduction pathways. 
 Activation of the FGF receptor leads to phosphorylation 
of a number of intracellular proteins, such as FGF receptor 
substrate 2 and phospholipase Cγ.32,33 Further downstream 
signaling is believed to be due to a combination of mitogen-
activated protein kinase and phosphatidylinositol 3-kinase/
Akt signaling, along with other pathways, being dominant 
in specific cell types or context.32,34,35
Role of FGF signaling  
in physiology and pathology
FGF signaling plays an important role in both embryogen-
esis and the adult organism, and during development FGF 
receptor signaling orchestrates a plethora of processes.35 FGF 
signaling is key to mesenchymal–epithelial interaction, and 
FGF receptors are well known inducers of mesoderm. In 
particular, endodermal to mesenchymal FGF signaling plays 
an important role in the development of the liver.36 Using an 
endoderm tissue explants system from mouse embryos, Jung 
et al showed that FGF signaling from the cardiac mesoderm is 
necessary for the induction of hepatic fate.37 Prior to hepatic 
induction, the cardiac mesoderm secretes FGF8, and at the 
time of hepatic development, secretes FGF1 and FGF2.38,39 
Detailed studies of embryonic tissue explants of the ventral 
foregut endoderm have shown that, in the absence of FGF sig-
naling from the cardiac mesoderm, the domain of the ventral 
foregut that is fated to become the liver rapidly defaults to the 
pancreas fate, by inhibiting pancreatic gene expression and 
inducing liver genes.37 Thus, the ventral foregut endoderm 
contains a bipotential precursor cell population for liver and 
pancreas, and FGF signaling diverts the endoderm from a 
default pancreas fate to that for the liver. In addition to the 
importance of FGF signaling for development of the liver, 
FGF receptor signaling is important for formation of the 
nervous system, the limbs, the midbrain, and the lungs.40 
FGF signaling also plays an important role in the develop-
ment of the embryonic mammary gland.41 In the adult, FGF 
receptor signaling regulates tissue repair, angiogenesis, and 
inflammation.40
Given the role of FGF signaling in the developing embryo 
and the adult, it is not surprising that this pathway is often 
hijacked by cancer cells.29 Indeed, the importance of FGF 
signaling in tumor pathogenesis was highlighted by a screen 
of more than 1,000 somatic mutations found in the coding 
exons of 518 protein kinase genes from over 200 different 
cancers. Of the non-synonymous mutations, FGF signaling 
was one of the most commonly mutated pathways.42 Several 
FGF receptor tyrosine kinase inhibitors and FGF receptor 
blocking antibodies are under various stages of preclinical 
and clinical development43 because of the oncogenic role of 
FGF in driving proliferation, survival, migration, invasion, 
and angiogenesis.44
Aberrant FGF signaling in HCC
HCC often emerges on a background of persistent liver 
injury, inflammation, and hepatocellular proliferation induced 
by cirrhosis or chronic hepatitis.45,46 This persistent injury 
induces aberrations in signaling pathways that give rise to 
early precursor lesions of HCC.32 These lesions respond to 
growth stimulatory cytokines and show increased proliferation 
and reduced cell death, providing a perfect environment for 
growth and expansion of cancer cells.47 Hepatocarcinogenesis 
is dependent on the development of a tumor-specific microen-
vironment in the cirrhotic liver composed of inflammatory 
cells, small vessels, myofibroblasts, and extracellular matrix 
components. These epithelial–mesenchymal interactions in 
the early and advanced stages of HCC are driven by various 
growth factors and their receptors.48 In addition to the signal-
ing pathways induced by hepatocyte growth factor and insulin-
like growth factors, aberrant FGF signaling is emerging as an 
important player in the development of liver tumors and their 
stroma.20,49 The main FGF receptors expressed in liver tissues 
are FGF receptors 3 and 4, and under normal conditions, FGF 
receptors 1 and 2 are expressed at low levels.50 Mounting evi-
dence suggests that aberrant signaling of these receptors and 
their ligands may be involved in the mechanisms underlying 
the tumorigenesis of HCC, and as such will be discussed in 
detail in the following section.
FGF8
The FGF8 subfamily ligands (FGF8, 17, 18) are thought 
to bind with high affinity to the IIIC isoforms of FGF 
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receptors 2 and 3 as well as FGF receptor 4.51 In normal adult 
homeostasis, FGF8 expression is restricted to steroid hormone 
target tissues. However, studies have shown that FGF8 is over-
expressed in hormone-responsive tumors such as prostate and 
breast cancer.52 Further, FGF17 is also deregulated in prostate 
cancer and FGF18 is frequently overexpressed in ovarian and 
colon cancers.53–55 In the liver, FGF18 expression can induce 
hepatocyte proliferation, leading to increased liver weight, 
and is upregulated in rat HCC, suggesting a gain of autocrine 
function of FGF18 in HCC.56 Importantly, analysis of human 
HCC cases has shown that the FGF8 subfamily, as well as FGF 
receptors 2, 3, and 4, are upregulated in epithelial HCC cells.20 
In vitro, members of the FGF8 subfamily are overexpressed in 
human HCC cells and contribute to the aggressive behavior of 
malignant hepatocytes under hypoxic conditions.20 Moreover, 
FGF8, FGF17, and FGF18 were able to induce neo-angiogen-
esis of hepatic endothelium and promoted growth of hepatic 
stellate cell-like cells found in the stroma of HCC patients,57 
suggesting that aberrant autocrine and paracrine FGF signal-
ing may drive development of HCC.20 Hepatic stellate cells 
were first described by Karl van Kuppfer in the 19th century 
as “sternzellen”, which were able to store vitamin A (retinol) 
as droplets in their cytoplasm.58 Hepatic stellate cells are the 
most abundant collagen-producing myofibroblast cells in the 
stroma of liver fibrosis, and are a target for therapy across 
different types of liver disease where fibrosis is prominent, 
including HCC.59 Involvement of stellate cells in the fibrotic 
response to liver injury has been recognized for several 
years.60,61 In response to repeated liver injury, hepatic stellate 
cells are activated and transdifferentiate into myofibroblast-like 
cells. Activated stellate cells are responsible for the produc-
tion of cytokines, growth factors such as FGF2 and epidermal 
growth factor, two potent epithelial growth factors that play 
an important role in the proliferation of hepatocytes as well 
as extensive production of extracellular matrix.57 Studies have 
shown activation and consequent proliferation of stellate cells 
in regions of greatest injury.62,63
Indeed, in HCC and biliary malignancy, activated stellate 
cells contribute to accumulation of the tumor stroma and 
play a role in driving hepatic metastasis.64,65 Further, in vitro 
studies have also shown that stellate cells cross-talk with 
tumoral cells, fuelling a vicious cycle of paracrine activa-
tion and proliferation.66 Indeed, we have recently identified a 
potential novel mechanism by which FGF signaling regulates 
pancreatic stromal cell behavior and cross-talk with pancre-
atic cancer cells.67 Other studies have shown that lipid-storing 
pancreatic stellate cells are abundant in the areas of fibrosis 
and are capable of secreting extracellular matrix proteins in 
patients with chronic alcoholic pancreatitis.68,69 These studies 
suggest that pancreatic stellate cells are a possible source of 
pancreatic fibrosis, similar to that observed in alcohol-related 
liver fibrosis. Further, pancreatic stellate cells are thought to 
be the key cell type driving the desmoplasia characteristic of 
pancreatic ductal adenocarcinoma and conferring resistance 
to conventional therapies.68,70 We have shown that both FGF2 
and FGF receptor 1 colocalize to the nucleus exclusively in 
pancreatic stellate cells at the invasive front of human pan-
creatic ductal adenocarcinoma.67 Using a three-dimensional 
organotypic model of pancreatic ductal adenocarcinoma 
developed in our laboratory to explore the cross-talk between 
pancreatic stellate cells and cancer cells, we showed that 
pancreatic stellate cells with nuclear FGF receptor 1 and 
FGF2 led cancer cells to invade the underlying extracel-
lular matrix.71 Thus, nuclear FGF receptor 1 and FGF2 in 
activated stromal pancreatic stellate cells may facilitate 
invasion of pancreatic stellate cells at the invasive front of 
pancreatic ductal adenocarcinoma. FGF receptor inhibition 
profoundly blocked invasion of both pancreatic stellate cells 
and cancer cells, and resulted in cytoplasmic localization of 
FGF receptor 1 and FGF2. These findings suggest a novel 
therapeutic approach, where preventing nuclear FGF/FGF 
receptor-mediated proliferation and invasion in pancreatic 
stellate cells leads to disruption of the tumor microenviron-
ment, preventing invasion of pancreatic cancer cells. Pan-
creatic stellate cells are nearly identical to hepatic stellate 
cells, and both are thought to share a common origin,72 thus 
targeting FGF signaling in hepatic stellate cells may offer a 
therapeutic target in HCC.
FGF receptor 1
FGF receptor 1 expression is low in normal liver epithelium. 
Recently, Wang et al have identified high expression of FGF 
receptor 1 in the tumor epithelium of patients with HCC.73 
In the prostate epithelium, FGF receptor 1 regulates matrix 
turnover and cell invasion by affecting expression of matrix-
degrading enzymes, and overexpression of FGF receptor 1 
is associated with an aggressive phenotype in prostate and 
breast cancer.74,75 Thus, FGF receptor 1 may function in inva-
sion of cancer cells. How overexpression of FGF receptor 1 
is regulated in HCC is not well understood. Recent studies 
have suggested that FGF receptor 1 may be under the control 
of the microRNA, miR-214.73 Deregulation of microRNAs 
is involved in the development of cancer and can be related 
to clinical outcome in cancer patients, including those with 
HCC.76,77 While microRNA overexpression has been seen 
in some cancers, including HCC, it appears that expression 
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of miR-214 may inhibit development of HCC by target 
regulation of FGF receptor 1 gene expression.73 Indeed, it 
has been previously reported that reduced expression of 
miR-214 contributes to intrahepatic metastasis of cholan-
giocarcinoma by targeting Twist.78 In HCC cells, miR-214 
has been reported to directly interact with FGF receptor 1, 
and its downregulation in HCC correlates with high FGF 
receptor 1 expression promoting invasion of HCC cells.79 
Thus, during tumor progression, decreased miR-214 levels 
and subsequent overexpression of FGF receptor 1 may play 
a role in promoting the aggressiveness of HCC.
FGF19 and FGF receptor 4
The FGF receptor 4–FGF19 signaling axis is an attractive 
target for progression of HCC for several reasons.17,18,80,81 
Firstly, the main FGF receptors expressed in the liver are FGF 
receptors 3 and 4, and the hepatocyte is the only human cell 
type in which FGF receptor 4 is the predominant isoform of 
FGF receptors.82 Secondly, it is reported that the liver has the 
highest transcript expression of FGF receptor 4 compared 
with other organs, as well as high expression of βklotho, 
which is required for the liver-specific activities of FGF19.82 
Thirdly, in the normal liver, hepatocyte FGF19 and FGF 
receptor 4 regulate biosynthesis in the bile duct by repres-
sion of the bile acid enzyme, cholesterol 7 α-hydroxylase.83,84 
However, ectopic expression of FGF19 (in skeletal muscle) 
but not FGF21 in mice, is sufficient to induce hepatocyte 
proliferation, dysplasia, and neoplasia, suggesting that spe-
cific aberration in FGF19-FGF receptor 4 signaling may have 
a strong pathophysiological impact in the liver.85,86 Indeed, 
recent reports have shown that a neutralizing antibody that 
selectively blocks the interaction between FGF receptor 4 
and FGF19 inhibits the growth of xenograft colon and liver 
tumors in vivo.81
Performing a comprehensive mutation analysis of 
57 human HCC and normal tissue samples, Ho et al found 
that FGF receptor 4 harbored eight tumor-associated genetic 
alterations, including two very common single nucleotide 
polymorphisms, ie, V101 and G338R. Approximately one 
third of the HCC samples overexpressed FGF receptor 4 when 
compared with normal tissues. Further, patients who harbored 
the G338R single nucleotide polymorphism secreted greater 
amounts of alpha-fetoprotein, a widely used biomarker for 
HCC. In vitro studies have shown that this polymorphism 
is important for production of alpha-fetoprotein as well as 
proliferation and survival of HCC cells.87 Moreover, the 
G388R mutation is more common in Asian populations than 
in other ethnicities. This single nucleotide polymorphism 
association, if validated in a larger study, could have important 
consequences for development of HCC and could possibly 
act as a predictive marker, since these single nucleotide poly-
morphisms may modify FGF receptor function, particularly 
in Asian populations with a high incidence of HCC.88 Using 
a genome wide approach, Sawey et al identified 18 tumor-
promoting genes that are amplified in human HCC, of which 
FGF19 was one of the most important.18 Gene amplification 
does not always correspond to increased expression of FGF19, 
and this may be tissue-specific. For example, FGF19 was 
found not to be overexpressed despite gene amplification in 
oral cancer, lung cancer, and melanoma.18,89 However, in HCC, 
amplification of FGF19 correlates with strong overexpression. 
Orthotopic transplantation of hepatocytes with amplified 
FGF19 resulted in highly proliferative tumors. Furthermore, 
following inhibition of FGF19 with RNA interference or a 
FGF19 monoclonal antibody, the clonal growth and tumori-
genicity of human HCC cells harboring the FGF19 amplicon 
was blocked.18 This suggests that FGF19 is an oncogene which 
is amplified and overexpressed in HCC and is a promising 
target for therapy. Indeed, overexpression of FGF19 in human 
HCC was found to be an independent prognostic factor for 
a poor response.17
FGF receptor 2iiib
In the normal liver, FGF receptor 2IIIb is expressed on 
hepatocytes and plays a role in liver regeneration and 
homeostasis.90 However, expression of FGF receptor 2IIIb 
is downregulated or lost in many HCC cell lines and tissues, 
and as a consequence can induce growth of HCC cells in vitro 
and in tumor xenografts,91 suggesting a tumor-suppressive 
role. This seemingly paradoxical role of FGF receptors 
in tumor development is not well understood, particularly 
as FGF receptors are reported to be potent oncogenes in 
tumorigenesis.29 However, HCC is not unique in this respect. 
FGF receptor 2IIIb is downregulated in several cancers, 
including those of the bladder and prostate, and loss of func-
tion mutations in the FGF receptor 2 gene has been detected 
in malignant melanoma.92 One possible explanation for this 
phenomenon is that the non-phosphotyrosine-containing 
region within the C-terminal part of FGF receptor 2IIIb may 
play a key role in FGF receptor 2IIIb-induced inhibitory 
signals in some tumors, such as HCC.93
Cross-talk of FGF and other 
signaling pathways in HCC
An additional manner by which signaling molecules can elicit 
distinct responses in different cell types is through activation 
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or repression of other signaling pathways. This cross-talk 
between signaling pathways results from specific interactions 
between signal transducing molecules, and convergence or 
divergence of the programs for gene expression activated by 
each pathway. Importantly, FGFs have been shown to interact 
with a number of signaling pathways in a variety of develop-
mental systems and, in some cases, simultaneous activation 
of these signaling pathways leads to effects that are distinct 
from the individual effects of each factor.94
One such example is that of the interaction between the 
WNT and FGF signaling pathways. WNT family members 
are secreted glycoproteins that bind to Frizzled transmem-
brane receptors and the LRP5/LRP6 coreceptor on the cell 
surface.95 A key event in the canonical WNT pathway is 
the activation of β-catenin, which subsequently regulates 
transcription of specific target genes that modulate cell 
proliferation and apoptosis.96 β-catenin is a dual function 
protein that plays a key role in maintaining cell–cell adhe-
sion via association of E-cadherin and linking cadherins to 
the cytoskeleton as well as the canonical and noncanonical 
WNT signaling cascade.97 Activation of WNT signaling in 
carcinogenesis leads to induction of FGF signaling activa-
tion and induces epithelial–mesenchymal transition.98 Thus, 
coactivation of the WNT and FGF signaling pathways 
leads to a more malignant phenotype in carcinogenesis. 
For example, treatment with FGF2 promotes translocation 
of β-catenin to the nucleus and maintains the proliferation 
of multipotent neural stem cells.99 Indeed, recent results 
from our group suggest that pancreatic cancer cells show 
active WNT signaling. Given that FGF2 is readily secreted 
by pancreatic stellate cells in pancreatic ductal adenocar-
cinoma, this may be one way in which FGF signaling may 
modulate the effect of WNT signaling in cancer cells and 
fuel an increase in tumor cell growth.100
In certain contexts, for example, in colorectal carcino-
genesis, coactivation of WNT and FGF signaling pathways 
in tumors, such as FGF19, directly modulating β-catenin 
signaling by loss of β-catenin/E-cadherin binding, leads 
to a more malignant phenotype.101 Further, inhibition of 
FGF19 signaling reduces β-catenin signaling. This cross-
talk is apparent in HCC, whereby overexpression of FGF19 
can induce β-catenin activity and lead to elevation of the 
β-catenin downstream target cyclin D1 protein.18 Along 
with FGF19, cyclin D1 is an important oncogene in HCC 
and can drive tumorigenesis.18 Importantly, blocking FGF19 
signaling abolishes β-catenin activation, and when HCC 
cells are treated with small interfering RNA to β-catenin, 
FGF19 can no longer induce cyclin D1 activity. Thus, in 
addition to the well established pathway involving RAS/
RAF/mitogen-activated protein kinase signaling, FGF19 is 
able to induce expression of cyclin D1 through β-catenin 
signaling in HCC cells.18 Further, deregulated Wnt/β-catenin 
signaling is able to transform stem/progenitor cells in the 
liver and as such may play an important role in the main-
tenance of liver cancer stem cells.102 WNT/β-catenin can 
directly target the hepatic progenitor cell marker EpCAM 
and induce its expression in HCC.103 A number of EpCAM-
regulated target genes have been identified, including c-myc 
and cyclins, which regulate cell proliferation, growth, and 
survival.104 Studies by Yang et al have shown that poorly dif-
ferentiated HCC cells characterized by the hepatic progeni-
tor marker OV6 are enriched in response to overexpression 
of WNT/β-catenin. Importantly, in these studies, silencing 
of β-catenin prevents the development of chemoresistant 
HCC populations, which demonstrate progenitor-like char-
acteristics.105 Further, Mavila et al have recently shown that 
treatment of well characterized tumor-initiating liver stem 
cells (CD133-expressing tumor-initiating cells isolated 
from the livers of methionine adenosyltransferase 1A null 
mice106) with recombinant FGF7 or FGF10 is sufficient to 
induce nuclear translocation of β-catenin and subsequent 
proliferation of progenitor cells.107 Thus, further under-
standing of the cross-talk between FGF and WNT signaling 
could aid in the development of therapeutics that target this 
signaling pathway in progenitor/cancer stem cells, reducing 
chemoresistance in HCC.
Abnormal vascularity of HCC is harnessed in the key 
diagnostic test by analyzing the differential perfusion of 
liver lesions on computed tomography and magnetic reso-
nance scans. HCC vessels are excessively leaky and have 
arteriovenous shunts. Although HCC is a highly angiogenic 
 cancer, it is also characterized by hypoxia which may promote 
growth and resistance of HCC to therapies.108 Studies have 
shown that inducing vessel normalization and preventing 
hypoxia can reduce growth of HCC.109 Amongst some of the 
best characterized angiogenic factors that are often secreted 
by cancer cells are FGF2 and VEGF.110 FGFs are key factors, 
particularly in tumor angiogenesis.111,112 FGF2 is a known 
mitogen for a number of cells, including myofibroblasts and 
vascular endothelial cells, and is often overexpressed in a 
number of cancers, including HCC.19,110 Indeed, in a clinical 
study of patients undergoing resection of HCC, a high pre-
operative serum FGF2 level was predictive of tumor invasion 
and recurrence.19 In addition to FGF2, levels of VEGF in 
serum are elevated in patients with HCC and correlate with 
a poor response to chemoembolization.113
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Studies have shown that VEGF and FGF2 have synergistic 
effects as inducers of angiogenesis.114 FGF2 is able to induce 
overexpression of VEGF and its receptor (VEGF receptor 
1) in endothelial cells and several other cell types. Addi-
tion of exogenous VEGF and FGF2 to three-dimensional 
microvascular endothelial cell cultures can induce cellular 
invasion and capillary-like tubule formation to a greater 
extent than addition of each growth factor alone. In vivo, 
xenografts simultaneously treated with FGF2 and VEGF 
show fast growing tumors with high blood vessel density, 
patency, and permeability. Further, angiogenesis enhanced 
by FGF2 can be significantly inhibited using a VEGF neu-
tralizing antibody and, under certain circumstances, FGF 
receptor signaling may mediate resistance to VEGF recep-
tor targeting.114,115 In HCC, the combined effect of FGF2 
and VEGF increases tumor growth and angiogenesis as 
tested by inducible expression of FGF2 or VEGF in vivo.116 
Further, overexpression of FGF2 can induce expression of 
VEGF, which leads to an increase in tumor development, 
and FGF2-induced augmentation is suppressed using the 
monoclonal antibody to VEGF receptor 1.117 These results 
suggest that VEGF is located downstream of FGF2 and 
together they can synergistically increase VEGF-mediated 
development of HCC.
Finally, studies by Ueba et al have shown that FGF2 
may be under the control of mutated p53 in HCC.118 p53 
is a nuclear phosphoprotein that regulates expression of 
various genes in the manner of sequence-specific DNA 
binding and or/protein-protein interactions, and is often 
mutated in cancers, including HCC.119,120 Using HCC cell 
lines transfected with a dominant negative mutant p53, they 
showed that mutant p53 was able to induce FGF2 promoter 
activity, while wild-type p53 repressed it.118 These findings 
demonstrate one possible mechanism for FGF2 activity in 
HCC tumor progression. Loss of normal function of p53 
may trigger activation of FGF2 transcription, resulting in 
tumor progression.
Therapeutic options
Several chemotherapeutic agents have been evaluated for 
the treatment of HCC; however, no single or combination 
therapy regimen is particularly effective.121 Prior to the advent 
of sorafenib, doxorubicin was routinely used as a single drug 
for advanced HCC. However, despite initial encouraging 
reports for single-agent doxorubicin, this has proven to lack 
efficacy, with a response rate of about 15%–20%.122,123 Other 
chemotherapy agents, such as epirubicin, cisplatin, 5-fluo-
rouracil, etoposide, and their combinations demonstrate even 
lower efficacy.123 Sorafenib, a multitargeted tyrosine kinase 
inhibitor, is the first targeted therapy to improve the survival 
of patients with advanced stage HCC in Phase III trials.124 
Sorafenib was designed to target VEGF receptors 1–3; 
however, the exact mechanism of action of this drug in HCC 
patients is still unknown.108,125 No effective second-line treat-
ment options currently exist for patients who are resistant 
or refractory to and/or intolerant of sorafenib.125 Given the 
pathogenetic role of FGF/FGF receptor signaling in HCC, 
treatment targeting FGF signaling may benefit patients. 
Several novel FGF receptor-targeted agents (multikinase 
inhibitors and monoclonal antibodies) are currently being 
developed and explored for HCC (Table 2).
Dual inhibition of veGF  
and FGF receptors
Adding to the challenges of single-target inhibition of VEGF, 
recent data suggest that although VEGF inhibitors reduce 
primary tumor growth, they also promote tumor invasiveness 
and metastasis.126 Given that FGF signaling may contribute 
to acquired resistance or compensatory signaling during anti-
VEGF receptor therapy, simultaneous inhibition of these two 
pathways may provide a mechanism to overcome resistance 
to VEGF-targeted agents in HCC.127 TSU-68 (SU6668; Taiho 
Pharmaceuticals Co, Ltd, Tokyo, Japan) is a dual inhibitor 
of VEGF receptor 2 and FGF receptors 1–3.79 Preclinical 
reports show that treatment with brivanib can inhibit growth 
of HCC and that TSU-68 can normalize tumor vasculature 
in xenograft mouse models.128 Brivanib has demonstrated 
activity against several types of solid tumors in clinical trials 
and is currently under investigation in many cancer types.129 
Data from a single-arm Phase II study in advanced HCC have 
demonstrated the antitumor activity of brivanib in first-line 
and second-line therapy.128 Brivanib is being evaluated in 
the first-line setting versus sorafenib in Phase III studies 
and in the second-line setting in patients with refractory 
advanced stage HCC by the Brivanib Study in Patients at 
Risk trials (BRISK-FL, BRISK-PS, and BRISK-APS).125 
Despite brivanib showing promise in early Phase II trials, 
recent results show that the BRISK-PS study did not meet 
its primary endpoint of improving overall survival. However, 
treatment with brivanib did result in overall improvement 
in cancer response rates.130 Similarly, the BRISK-FL trial, 
directly comparing clinical outcomes of brivanib versus 
sorafenib in patients with advanced HCC who had received 
no prior systemic therapy, failed to demonstrate a statistically 
significant difference in overall survival (9.5 months versus 
9.9 months).125 TSU-68 has demonstrated some clinical 
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efficacy in a Phase I/II trial of heavily pretreated patients with 
advanced HCC who had a mean survival of 13.1 months, 
suggesting that TSU-68 may have a clinical benefit in 
patients with advanced HCC. A larger randomized Phase 
III study is now recruiting patients with unresectable HCC 
to evaluate transcatheter arterial chemoembolization in 
combination with either TSU-68 or placebo.131
Multitarget tyrosine receptor  
kinase inhibitors
Dovitinib (TKI 258; Novartis, Basel, Switzerland) is an 
inhibitor of FGF, PDGF, and VEGF receptors and has shown 
promising activity in early-phase trials in solid tumors.132 
Dovitinib is currently being tested in a Phase II study to 
compare its safety and efficacy versus that of sorafenib as 
first-line treatment in adult patients with advanced HCC, with 
overall survival as the primary endpoint. Patient recruitment 
has finished and the study is planned to be completed later 
in the year.133
Lenvatinib (E7080; Eisai Co, Ltd, Tokyo, Japan) is an 
orally administered tyrosine kinase inhibitor that targets 
VEGF receptors 1–3 and FGF receptors 1–4. After show-
ing preliminary antitumor activity and safety profile in 
a Phase I/II study, a randomized, double-blind Phase III 
study is currently comparing the efficacy and safety of 
lenvatinib versus sorafenib in the first-line treatment of 
patients with unresectable HCC (ClinicalTrials.gov identi-
fier NCT01761266).133,134 Finally, early-phase studies are 
ongoing in HCC patients to test the safety and tolerability 
of the multikinase inhibitor nintedanib (BIBF 1220; 
Boehringer Ingelheim, Rhineland-Palatinate, Germany) 
which targets VEGF receptors 1–3, FGF receptors 
1–3, and PDGF receptors (ClinicalTrials.gov identifier 
NCT01594125).
Table 2 Novel targeted multikinase inhibitors currently being investigated in clinical trials for hepatocellular carcinoma
Agent Target Trial Efficacy Reference
Brivanib FGFR 1–3 
PDGFR 
veGFR 1–3
Phase iii, BRiSK-FL. Randomized, double-blind, multi-center Phase iii  
study of brivanib versus sorafenib as first-line treatment in patients  
with advanced hepatocellular carcinoma (NCT00858871) 
Phase iii, BRiSK PS. A randomized, double-blind, multi-center  
Phase iii study of brivanib plus best supportive care (BSC) versus  
placebo plus BSC in subjects with advanced hepatocellular  
carcinoma (HCC) who have failed or are intolerant to sorafenib.  
(NCT00825955) 
Phase iii, BRiSK APS. A randomized, double-blind, multi-center  
Phase iii study of brivanib plus best supportive care (BSC) versus  
placebo plus BSC in Asian subjects with advanced hepatocellular  
carcinoma (HCC) who have failed or are intolerant to sorafenib  
(NCT01108705) 
Phase iii, BRiSK-TA. A randomized, double-blind, multicenter  
Phase iii study of brivanib versus placebo as adjuvant therapy  
to trans-arterial chemo-embolization (TACe) in patients with  
unresectable hepatocellular carcinoma (NCT00908752)
Median OS was 9.9 months for 
sorafenib versus 9.5 months  
for brivanib 
Median OS was 9.4 months for 
brivanib versus 8.2 months for 
placebo 
 
 
Ongoing 
 
 
 
 
Ongoing
130 
 
 
139 
 
 
 
 
133 
 
 
 
 
133
TSU-68  
(orantinib)
FGFR 
PDGFR 
veGFR
Phase iii, ORieNTAL trial. A randomized, double-blind,  
placebo-controlled Phase iii trial of TSU-68 in combination  
with transcatheter arterial chemoembolization in patients with  
unresectable hepatocellular carcinoma (NCT01465464)
Ongoing 131
Dovitinib  
(TKi-258)
FGFR 
veGFR 
PDGFR
Phase ii. An open-label, randomized, multi-center, Phase ii study  
to compare the safety and efficacy of TKI258 versus sorafenib as  
first-line treatment in adult patients with advanced hepatocellular  
carcinoma (NCT01232296)
Ongoing 133
Lenvatinib  
(e7080)
FGFR 
veGFR 
PDGFR 
ReR 
KiT
Phase i/ii. Phase i/ii study of e7080 in patients with advanced  
hepatocellular carcinoma (HCC) (NCT00946153) 
Phase iii. A multicenter, open-label, Phase iii trial to compare  
the efficacy and safety of lenvatinib (E7080) versus sorafenib in  
first-line treatment of subjects with unresectable hepatocellular  
carcinoma (NCT01761266)
Ongoing 
 
Recruiting
134 
 
133
Nintedaninb  
(BiBF 1120)
FGFR 
PDGFR 
veGFR
Phase i. An open label, dose escalation Phase i study to evaluate  
the safety and tolerability of continuous twice-daily oral  
treatment of nintedanib in Japanese patients with hepatocellular  
carcinoma (NCT01594125)
Recruiting 133
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Conclusion
To date, many of these targeted therapies have shown little 
liver toxicity, which is surprising given the role of FGF 
receptors in normal liver physiology. This may be explained 
by the failure of many multikinase inhibitors to target FGF 
receptor 4, which has a major role in normal hepatocytes. 
FGF receptor 4 shows the lowest degree of homology with 
other FGF receptor family members, and as such none of 
the small-molecule tyrosine kinase inhibitors developed so 
far show specificity for FGF receptor 4.135 This may also 
explain why some of these targeted therapies, such as sra-
vanib, have not achieved overall survival endpoints in larger 
Phase III trials, given that FGF receptor 4 has been shown 
to play a major role in the development and aggressiveness 
of HCC. Thus, patients may need to be selected on the basis 
of their FGF status to achieve more efficacious results in the 
trial setting. Nevertheless, given the important metabolic 
functions of FGF receptor 4 in the liver, the side effects of 
an FGF receptor 4-specific inhibitor should be carefully 
considered.136 FGF receptor 4 null mice show elevated 
cholesterol metabolism and bile acid synthesis and were 
vulnerable to liver damage.83 However, studies have shown 
that blocking FGF receptor 4 activity (either biochemi-
cally or genetically, as discussed above) has an anticancer 
effect, particularly in cancers overexpressing FGF receptor 
4. Therefore, it is important to develop an FGF receptor 
4-specific inhibitor in order to clarify the importance of 
this therapeutic strategy in patients harboring FGF receptor 
4 mutations. Recently, in silico design has identified FGF 
receptor 4 inhibitors as potential anticancer agents that have 
shown promise in early in vitro studies.137 Further, blocking 
FGF receptor 4 in some instances has led to selection of 
subpopulations of treatment-refractory cells, and should be 
considered when targeting FGF receptor 4-mediated signal-
ing in HCC in order to prevent development of resistance 
to therapy.138
However, given the importance of FGF receptor signaling 
in the development of HCC, and the clinical trial testing of 
promising new kinase inhibitors that target FGF receptors, 
there is promise for improving the prognosis of HCC patients 
who have limited therapeutic options.
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